Stereotactic Body Radiotherapy for Centrally Located Primary Non-Small-Cell Lung Cancer: A Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Tosol | - |
dc.contributor.author | Shin, In-Soo | - |
dc.contributor.author | Yoon, Won Sup | - |
dc.contributor.author | Rim, Chai Hong | - |
dc.date.accessioned | 2021-09-01T13:31:41Z | - |
dc.date.available | 2021-09-01T13:31:41Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 1525-7304 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/64676 | - |
dc.description.abstract | The feasibility of stereotactic body radiotherapy (SBRT) for centrally located tumors is controversial. SBRT with 100 Gy or higher biologically equivalent dose using an alpha/beta of 10 Gy for centrally located primary NSCLC offered excellent local control (3years; 77.6% [95% confidential interval, 65.2-86.5]), comparable with that of other SBRT reports for peripheral lung tumors. The pooled rate of Grade >= 3 complications was 12.0%. This suggest that SBRT can be used in inoperable centrally located lung tumors with a curative intent. Background: The purpose of the study was to evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for centrally located, primary non-small-cell lung cancer (NSCLC). Materials and Methods: Systematic search of 4 databases (PubMed, MEDLINE, EMBASE, and Cochrane Library) was performed for literature published until May 9, 2018. Primary (overall survival [OS] and local control [LC] rates) and secondary (Grade >= 3 toxicity) endpoints were reported. Results: Thirteen studies encompassing 599 patients with central NSCLCs were included. Median values of T1 tumor proportion, tumor size, and median survival were 55.3% (range, 0%-75%), 3.3 (range, 2.1-4.1) cm, and 26 (range, 14-68.9) months, respectively. Pooled rates of 1-, 2-, and 3-year OS rates were 84.3% (95% confidence interval [CI], 75.7-90.3), 64.0% (95% CI, 52.9-72.2), and 50.5% (95% CI, 39.4-61.5), respectively. Pooled rates of 1-, 2-, and 3-year LC rates were 89.4% (95% CI, 80.8-94.4), 82.2% (95% CI, 71.7-89.4), and 72.2% (95% CI, 55.0-84.7), respectively. Pooled rate of Grade >= 3 complication was 12.0% (95% CI, 7.3-19.0). Meta-regression analyses showed significant positive relationships between biologically equivalent dose using an alpha/beta of 10 Gy in the linear quadratic model (BED10Gy) and 1- and 2-year LC rates (P < .001 and P < .001), and 1- and 2-year OS rates (P = .0178 and P = .032), and Grade >= 3 complication rate (P = .0029). In subgroup comparisons between BED10Gy < 100 Gy versus >= 100 Gy, 1- and 2-year LC rates were significantly different but not for OS and Grade >= 3 complication rates. Conclusion: Our results suggests that SBRT is potent for tumor control in central NSCLC, although complications should be further minimized through optimization of dose-fractionation scheme and accurate planning. Using BED10Gy >= 100 Gy yielded higher LC rates, and dose escalation was related to OS, LC, and complications. (C) 2019 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | CIG MEDIA GROUP, LP | - |
dc.subject | ASSISTED THORACOSCOPIC SURGERY | - |
dc.subject | ONCOLOGY/RTOG 0813 TRIAL | - |
dc.subject | RADIATION-THERAPY SBRT | - |
dc.subject | EARLY-STAGE | - |
dc.subject | ABLATIVE RADIOTHERAPY | - |
dc.subject | PHASE-II | - |
dc.subject | TUMOR LOCATION | - |
dc.subject | TOXICITY | - |
dc.subject | OUTCOMES | - |
dc.subject | RISK | - |
dc.title | Stereotactic Body Radiotherapy for Centrally Located Primary Non-Small-Cell Lung Cancer: A Meta-Analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Won Sup | - |
dc.contributor.affiliatedAuthor | Rim, Chai Hong | - |
dc.identifier.doi | 10.1016/j.cllc.2019.02.023 | - |
dc.identifier.scopusid | 2-s2.0-85064611157 | - |
dc.identifier.wosid | 000475296800004 | - |
dc.identifier.bibliographicCitation | CLINICAL LUNG CANCER, v.20, no.4, pp.E452 - E462 | - |
dc.relation.isPartOf | CLINICAL LUNG CANCER | - |
dc.citation.title | CLINICAL LUNG CANCER | - |
dc.citation.volume | 20 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | E452 | - |
dc.citation.endPage | E462 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | ASSISTED THORACOSCOPIC SURGERY | - |
dc.subject.keywordPlus | ONCOLOGY/RTOG 0813 TRIAL | - |
dc.subject.keywordPlus | RADIATION-THERAPY SBRT | - |
dc.subject.keywordPlus | EARLY-STAGE | - |
dc.subject.keywordPlus | ABLATIVE RADIOTHERAPY | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | TUMOR LOCATION | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | Dose fractionation | - |
dc.subject.keywordAuthor | Network meta-analysis | - |
dc.subject.keywordAuthor | Non-small-cell lung carcinoma | - |
dc.subject.keywordAuthor | Radiosurgery | - |
dc.subject.keywordAuthor | Survival rate | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.